Down-regulation of ERAP1 mRNA expression in non-small cell lung cancer
Open Access
- 26 April 2023
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 23 (1) , 1-11
Abstract
Background: ERAP1 is a major aminopeptidase that serves as an editor of the peptide repertoire by trimming N-terminal residues of antigenic peptides, creating a pool of peptides with the optimal length for MHC-I binding. As an important component of the antigen processing and presenting machinery – APM, ERAP1 is frequently down-regulated in many cancers. Since ERAP1 expression has not yet been thoroughly investigated in non-small cell lung cancer (NSCLC), we decided to analyze ERAP1 mRNA levels in tissues collected from NSCLC patients. Methods: Using real-time qPCR, we evaluated ERAP1 mRNA expression in samples of tumor and adjacent non-tumor tissue (serving as control tissue) from 61 NSCLC patients. Results: We observed a significantly lower level of ERAP1 mRNA expression in tumor tissue (MedTumor = 0.75) in comparison to non-tumor tissue (MedNon-tumor = 1.1), p = 0.008. One of the five tested polymorphisms, namely rs26653, turned out to be significantly associated with ERAP1 expression in non-tumor tissue (difference [d] = 0.59 CI95% (0.14;1.05), p = 0.0086), but not in tumor tissue. The levels of ERAP1 mRNA expression did not affect the overall survival of NSCLC patients, either in the case of the tumor (p = 0.788) or in non-tumor (p = 0.298) tissue. We did not detect any association between mRNA ERAP1 expression level in normal tissue and: (i) age at diagnosis (p = 0.8386), (ii) patient’s sex (p = 0.3616), (iii) histological type of cancer (p = 0.7580) and (iv) clinical stage of NSCLC (p = 0.7549). Furthermore, in the case of tumor tissue none of the abovementioned clinical parameters were associated with ERAP1 expression (p = 0.76). Conclusion: Down-regulation of ERAP1 mRNA observed in NSCLC tissue may be related to tumor immune evasion strategy. The rs26653 polymorphism can be considered an expression quantitative trait locus (eQTL) associated with ERAP1 expression in normal lung tissue.Keywords
Funding Information
- Polish National Science Centre (OPUS 8 2014/15/B/NZ5/ 03517)
This publication has 30 references indexed in Scilit:
- Association between single nucleotide polymorphisms in prospective genes and susceptibility to ankylosing spondylitis and inflammatory bowel disease in a single centre in TurkeyTurkish Journal of Gastroenterology, 2016
- MHC Class I Antigen Processing and Presenting Machinery: Organization, Function, and Defects in Tumor CellsJNCI: Journal of the National Cancer Institute, 2013
- The Genotype-Tissue Expression (GTEx) projectNature Genetics, 2013
- Genetic Association with ERAP1 in Psoriasis Is Confined to Disease Onset after Puberty and Not Dependent on HLA-C*06Journal of Investigative Dermatology, 2013
- The Human Protein Atlas—a tool for pathologyThe Journal of Pathology, 2008
- Altered expression of endoplasmic reticulum aminopeptidases ERAP1 and ERAP2 in transformed non‐lymphoid human tissuesJournal of Cellular Physiology, 2008
- The IASLC Lung Cancer Staging Project: Validation of the Proposals for Revision of the T, N, and M Descriptors and Consequent Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant TumoursJournal of Thoracic Oncology, 2007
- Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinomaCancer Immunology, Immunotherapy, 2007
- The aminopeptidase ERAAP shapes the peptide repertoire displayed by major histocompatibility complex class I moleculesNature Immunology, 2005
- Alternatives to the Median Absolute DeviationJournal of the American Statistical Association, 1993